- Home
- IPSC
as 10-15-2025 4:00pm EST
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 49.1M | IPO Year: | 2021 |
| Target Price: | $3.33 | AVG Volume (30 days): | 730.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $1.83 | Next Earning Date: | 11-04-2025 |
| Revenue: | $114,128,000 | Revenue Growth: | 5491.77% |
| Revenue Growth (this year): | 1589.94% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pfeiffenberger Brent | IPSC | President and CEO | Sep 8 '25 | Sell | $0.50 | 488 | $244.00 | 3,268,909 | |
| Russotti Gregory | IPSC | See Remarks | Sep 8 '25 | Sell | $0.50 | 539 | $269.50 | 391,508 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Sep 8 '25 | Sell | $0.50 | 263 | $131.50 | 405,423 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Simply Wall St.
4 days ago
We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully
Zacks
4 months ago
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Zacks
4 months ago
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
GlobeNewswire
5 months ago
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
MT Newswires
5 months ago
Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating
Zacks
5 months ago
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
GlobeNewswire
5 months ago
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Compare IPSC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.